Welcome!

News Feed Item

Conference Schedules, Upcoming Marathon Applications, Revised Guidance, and Acquisitions - Analyst Notes on Celgene, Medtronic, Alexion, Quest Diagnostics, and Illumina

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, March 14, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Celgene Corporation (NASDAQ: CELG), Medtronic, Inc. (NYSE: MDT), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), Quest Diagnostics Inc (NYSE: DGX) and Illumina, Inc. (NASDAQ: ILMN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

--

Celgene Corporation Analyst Notes

On its events page, Celgene Corporation (Celgene) posted the schedule of two upcoming conferences that the Company will participate in during the ongoing month. Celgene will be a part of the American Academy of Dermatology (AAD) Annual Meeting at the Colorado Convention Center in Denver, CO, which will be held from March 21 to March 25, 2014. The Company will also take part in the European Lung Cancer Conference (ELCC) at Palexpo in Geneva, Switzerland, which will take place from March 26 to March 29, 2014.  The full analyst notes on Celgene Corporation are available to download free of charge at:

http://www.AnalystsReview.com/03142014/CELG/report.pdf

--

Medtronic, Inc. Analyst Notes

On March 10, 2014, Medtronic, Inc. (Medtronic) announced that the applications for runners around the world who benefit from medical technology to represent their country on the 2014 Medtronic Global Heroes team are now open. According to Medtronic, up to 25 runners will be chosen to receive a paid entry for themselves and a guest to the Medtronic Twin Cities Marathon or the Medtronic TC 10 Mile. The Company informed that the 2014 Medtronic Twin Cities Marathon weekend will take place from October 3 to October 5, 2014, and that the deadline for application is April 25, 2014. The full analyst notes on Medtronic, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03142014/MDT/report.pdf

--

Alexion Pharmaceuticals, Inc. Analyst Notes

On March 10, 2014, Alexion Pharmaceuticals, Inc. (Alexion) revised its previously announced 2014 financial guidance for net product sales and non-GAAP earnings per share (EPS). Alexion stated that its 2014 net revenue guidance has been increased to a range of $2,150 to $2,170 million from its prior guidance range of $2,000 to $2,020 million. The Company said that it will record increased revenue in 2014 related to an agreement that brings to conclusion discussions with the French government and which positively impacts prospective reimbursement of Soliris. Non-GAAP EPS is now expected in the range of $4.37 to $4.47, up from the Company's previous expectation of $3.70 to $3.80. The full analyst notes on Alexion Pharmaceuticals, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03142014/ALXN/report.pdf

--

Quest Diagnostics Inc. Analyst Notes

On March 11, 2014, Quest Diagnostics Inc. (Quest Diagnostics) announced that it has entered into an agreement to acquire Summit Health - a leading provider of on-site prevention and wellness programs mainly for employees. Steve Rusckowski, President and CEO, Quest Diagnostics, stated "This acquisition supports Quest Diagnostics' five-point strategy, which includes restoring growth and driving disciplined capital deployment. One of our capital deployment objectives is to grow one to two percent a year through strategically aligned, accretive acquisitions." Terms of the transaction were not disclosed. The full analyst notes on Quest Diagnostics Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03142014/DGX/report.pdf

--

Illumina, Inc. Analyst Notes

On March 10, 2014, Illumina, Inc. (Illumina) and WuXi PharmaTech (Cayman) Inc. announced that the Wuxi Genome Center has purchased an Illumina HiSeq X Ten sequencing system. The Company informed that HiSeq X Ten is the world's first platform to deliver full coverage human genomes. Illumina stated that the purchase will enable WuXi's clinical genomic services to expand from the current target panel, exome, and transcriptome scale sequencing to population genome scale sequencing, putting the world's most advanced gene sequencing capability in the hands of the leading pharmaceutical R&D services company in the Asia Pacific region. "This investment in cutting-edge gene sequencing technology significantly strengthens WuXi's broad, integrated platform of R&D services," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "It advances our mission of enabling anyone and any company to use our R&D platform to discover and develop innovative medicines to benefit the world's patients." The full analyst notes on Illumina, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03142014/ILMN/report.pdf

--


About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

--

=============

EDITOR NOTES:

  • This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  • Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  • This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  • If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
  • For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
  • Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


AnalystsReview.com

SOURCE Analysts Review

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that Isomorphic Software will exhibit at DevOps Summit at 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Isomorphic Software provides the SmartClient HTML5/AJAX platform, the most advanced technology for building rich, cutting-edge enterprise web applications for desktop and mobile. SmartClient combines the productivity and performance of traditional desktop software with the simp...
The 19th International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Digital Transformation, Microservices and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding business opportuni...
19th Cloud Expo, taking place November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy. Meanwhile, 94% of enterpri...
Kubernetes, Docker and containers are changing the world, and how companies are deploying their software and running their infrastructure. With the shift in how applications are built and deployed, new challenges must be solved. In his session at @DevOpsSummit at19th Cloud Expo, Sebastian Scheele, co-founder of Loodse, will discuss the implications of containerized applications/infrastructures and their impact on the enterprise. In a real world example based on Kubernetes, he will show how to ...
Personalization has long been the holy grail of marketing. Simply stated, communicate the most relevant offer to the right person and you will increase sales. To achieve this, you must understand the individual. Consequently, digital marketers developed many ways to gather and leverage customer information to deliver targeted experiences. In his session at @ThingsExpo, Lou Casal, Founder and Principal Consultant at Practicala, discussed how the Internet of Things (IoT) has accelerated our abil...
With so much going on in this space you could be forgiven for thinking you were always working with yesterday’s technologies. So much change, so quickly. What do you do if you have to build a solution from the ground up that is expected to live in the field for at least 5-10 years? This is the challenge we faced when we looked to refresh our existing 10-year-old custom hardware stack to measure the fullness of trash cans and compactors.
Extreme Computing is the ability to leverage highly performant infrastructure and software to accelerate Big Data, machine learning, HPC, and Enterprise applications. High IOPS Storage, low-latency networks, in-memory databases, GPUs and other parallel accelerators are being used to achieve faster results and help businesses make better decisions. In his session at 18th Cloud Expo, Michael O'Neill, Strategic Business Development at NVIDIA, focused on some of the unique ways extreme computing is...
The emerging Internet of Everything creates tremendous new opportunities for customer engagement and business model innovation. However, enterprises must overcome a number of critical challenges to bring these new solutions to market. In his session at @ThingsExpo, Michael Martin, CTO/CIO at nfrastructure, outlined these key challenges and recommended approaches for overcoming them to achieve speed and agility in the design, development and implementation of Internet of Everything solutions wi...
DevOps at Cloud Expo, taking place Nov 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 19th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long dev...
Cloud computing is being adopted in one form or another by 94% of enterprises today. Tens of billions of new devices are being connected to The Internet of Things. And Big Data is driving this bus. An exponential increase is expected in the amount of information being processed, managed, analyzed, and acted upon by enterprise IT. This amazing is not part of some distant future - it is happening today. One report shows a 650% increase in enterprise data by 2020. Other estimates are even higher....
I wanted to gather all of my Internet of Things (IOT) blogs into a single blog (that I could later use with my University of San Francisco (USF) Big Data “MBA” course). However as I started to pull these blogs together, I realized that my IOT discussion lacked a vision; it lacked an end point towards which an organization could drive their IOT envisioning, proof of value, app dev, data engineering and data science efforts. And I think that the IOT end point is really quite simple…
Aspose.Total for .NET is the most complete package of all file format APIs for .NET as offered by Aspose. It empowers developers to create, edit, render, print and convert between a wide range of popular document formats within any .NET, C#, ASP.NET and VB.NET applications. Aspose compiles all .NET APIs on a daily basis to ensure that it contains the most up to date versions of each of Aspose .NET APIs. If a new .NET API or a new version of existing APIs is released during the subscription peri...
Today we can collect lots and lots of performance data. We build beautiful dashboards and even have fancy query languages to access and transform the data. Still performance data is a secret language only a couple of people understand. The more business becomes digital the more stakeholders are interested in this data including how it relates to business. Some of these people have never used a monitoring tool before. They have a question on their mind like “How is my application doing” but no id...
Identity is in everything and customers are looking to their providers to ensure the security of their identities, transactions and data. With the increased reliance on cloud-based services, service providers must build security and trust into their offerings, adding value to customers and improving the user experience. Making identity, security and privacy easy for customers provides a unique advantage over the competition.
Qosmos has announced new milestones in the detection of encrypted traffic and in protocol signature coverage. Qosmos latest software can accurately classify traffic encrypted with SSL/TLS (e.g., Google, Facebook, WhatsApp), P2P traffic (e.g., BitTorrent, MuTorrent, Vuze), and Skype, while preserving the privacy of communication content. These new classification techniques mean that traffic optimization, policy enforcement, and user experience are largely unaffected by encryption. In respect wit...